5-Amino-1MQ

5-Amino-1MQ is not a peptide at all — it is a small synthetic molecule built on a quinolinium ring, even though it is sold alongside peptides. It was designed in academic laboratories to block an enzyme called NNMT (nicotinamide N-methyltransferase), which sits inside fat cells and muscle cells and uses up nicotinamide, one of the raw materials your cells need to make NAD+ (nicotinamide adenine dinucleotide, a molecule central to how cells produce energy). The idea being tested is that if you slow NNMT down, fat cells keep more of that raw material and burn more fuel instead of storing it. Everything published so far about that idea comes from mice and from cells in a dish — as of today there are no published human trials, no registered clinical studies, and no regulatory approval anywhere.

• Fat loss and body recomposition, based on mouse studies of diet-induced obesity
• Muscle strength and recovery after injury, based on studies in aged mice
• Support alongside training, marketed as an exercise mimetic
• Metabolic markers such as cholesterol and glucose tolerance, again from rodent data
• General NAD+ and longevity interest, which is mechanistic reasoning rather than a demonstrated outcome

Think of nicotinamide as firewood your cells burn to make energy. NNMT is like a worker who keeps tagging logs as scrap and hauling them away before they reach the fire. 5-Amino-1MQ is meant to slow that worker down, so more wood stays in the pile and the fire burns hotter. In mice, that showed up as smaller fat cells and stronger muscle — whether the same thing happens in a person has not been tested.

1. Day 1Nothing published describes what a person feels on day one, because no human study of this compound exists.
2. Week 1–2In diet-induced obese mice, about eleven days of injections produced roughly 5 percent body weight loss and smaller fat cells (Neelakantan 2018).
3. Week 3–4Three weeks of dosing in aged, injured mice increased muscle fiber cross-sectional area about 1.5-fold versus controls (Neelakantan 2019).
4. Month 2+Eight weeks of daily dosing in 22-month-old mice raised grip strength around 40 percent versus sedentary controls (Dimet-Wiley 2024).
5. Long termNo study of any length has followed humans, so there is no evidence-based long-term timeline.

• No adverse events were reported in the studies located, which is not the same as none existing — every one of those studies was in mice or in cultured cells.
• In aged mice given 5 or 10 mg/kg twice daily, liver enzymes, glucose, cholesterol, plasma proteins and electrolytes did not differ from controls (Neelakantan 2019).
• In diet-induced obese mice, food intake was unchanged and no observable adverse effects were noted over eleven days of dosing (Neelakantan 2018).
• Gut bacteria composition shifted measurably in treated mice, with increased Lactobacillus and decreased Erysipelatoclostridium (Dimet-Wiley 2022); the consequences of that shift are not known.
• Because there is no human safety data at all, the side effect profile in people is unknown rather than reassuring.

• You are pregnant, trying to conceive, or breastfeeding — no reproductive or developmental safety data exists.
• You have a current or past cancer diagnosis; NNMT is heavily involved in tumor metabolism and inhibitors are being studied in oncology, so the effect of self-dosing is unpredictable.
• You have liver or kidney impairment, since clearance in humans has never been characterized.
• You are already taking NAD+ precursors, methyl donors, or other metabolic drugs — interactions have not been studied.
• You are not under the supervision of a physician who knows you are using an unapproved research compound.

• Treating it as a peptide. It is a small molecule, so reconstitution and storage advice copied from peptide protocols does not necessarily apply.
• Assuming oral capsules match the published data. Every rodent study located used subcutaneous injection; oral absorption in humans has not been reported.
• Scaling mouse milligram-per-kilogram doses directly to body weight. The rodent doses (5 to 32 mg/kg) are not human doses and do not translate one to one.
• Expecting fat loss without changing diet. In the mouse work the strongest effects came when the compound was paired with a switch to a lower-calorie or low-fat diet.
• Buying material labeled research use only without third-party purity testing, then attributing any symptom to the compound rather than to a contaminant.